Stark Focus Group, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Stark Focus Group, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $44.3K | Apr 12, 2021 |
| FY2020 | Dec 31, 2019 | $26.1K | Apr 12, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $8.9K | Apr 12, 2021 |
| FY2020 | Dec 31, 2019 | $3.1K | Apr 12, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($47.2K) | Apr 14, 2025 |
| FY2024 | Dec 31, 2023 | ($32.1K) | Apr 14, 2025 |
| FY2024 | Dec 31, 2022 | ($49.3K) | Apr 14, 2025 |
| FY2022 | Dec 31, 2021 | $59.5K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($91.9K) | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | ($8.0K) | Apr 12, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($43.2K) | Apr 14, 2025 |
| FY2024 | Dec 31, 2023 | ($30.5K) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($48.6K) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $114.3K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($90.5K) | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | ($8.0K) | Apr 12, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $9.5K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 23, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $54.3K | Apr 1, 2022 |
| FY2021 | Dec 31, 2020 | $90.5K | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $11.1K | Apr 12, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($40.8K) | Apr 14, 2025 |
| FY2024 | Dec 31, 2023 | ($30.5K) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($54.6K) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($64.0K) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($70.3K) | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | ($13.7K) | Apr 12, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Apr 14, 2025 |
| FY2024 | Dec 31, 2023 | $0 | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $6.0K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $3.1K | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $37.8K | Apr 12, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $140.7K | Apr 14, 2025 |
| FY2024 | Dec 31, 2023 | $93.5K | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $67.4K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $12.1K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $58.9K | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.8K | Apr 12, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($140.7K) | Apr 14, 2025 |
| FY2024 | Dec 31, 2023 | ($93.5K) | Apr 14, 2025 |
| FY2024 | Dec 31, 2022 | ($61.4K) | Apr 14, 2025 |
| FY2024 | Dec 31, 2021 | ($12.1K) | Apr 14, 2025 |
| FY2022 | Dec 31, 2020 | ($55.8K) | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | $36.0K | Apr 1, 2022 |
| FY2020 | Apr 10, 2019 | $1.3K | Apr 12, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($183.6K) | Apr 14, 2025 |
| FY2024 | Dec 31, 2023 | ($136.3K) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($104.3K) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($55.0K) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($99.9K) | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | ($8.0K) | Apr 12, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $3.1K | Apr 1, 2022 |
| FY2021 | Dec 31, 2019 | $30.3K | Apr 1, 2022 |
| FY2020 | Dec 31, 2018 | $0 | Apr 12, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 0 | Mar 23, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 14, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 14, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 9.95M | Apr 14, 2025 |
| FY2024 | Dec 31, 2023 | 9.95M | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | 9.95M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 9.95M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 10.22M | Apr 1, 2022 |
| FY2020 | Dec 31, 2019 | 10.22M | Apr 12, 2021 |